EyeBrain’s eye-tracker used in study of levodopa treatment for
18 December 2011
Ivry-sur-Seine, France. EyeBrain, a developer of devices for
the early diagnosis of neurological diseases, has announced that its
EyeBrain Tracker is being used in a clinical trial studying the
dyskinesia induced by treating patients suffering from idiopathic
Parkinson’s disease with levodopa.
The endpoint of the trial is to find biomarkers for the
late-onset complications of a treatment regime using levodopa
(BIODYS). This compound, which is naturally transformed into
dopamine in the brain, is one of the only drugs available for
slowing the effects of Parkinson’s disease. However, over time, it
induces dyskinesia in these patients, which takes the form of
abnormal movements primarily affecting the face (tongue, lips, jaw)
and extending as far as the arms and legs.
Altogether, 30 people will be enrolled on the trial. Half of them
will be Parkinson’s sufferers who have been treated with levodopa
and have developed dyskinesia, while the other half will consist of
healthy subjects who will be used as a control group.
The trial is being sponsored and financed by Bordeaux University
Hospital and was set up by professor Jean-François Tison, a
neurologist attached to the CNRS Physiopathology of Parkinsonian
syndromes unit at the University of Bordeaux Two (the Institute of
Neurodegenerative Diseases). The EyeBrain Tracker device is being
funded under the joint 2007-2013 State-Region Plan (Aquitaine
Regional Council and the FEDER fund).
“Patients suffering from idiopathic Parkinson’s disease will
undergo an acute test as part of a pre-operational assessment for
stimulating the deep recesses of the brain,” explained professor
Tison. The motricity effects of the treatment will be evaluated by
measuring the speed of eye movements with the help of the EyeBrain
“We will see whether levodopa modifies the parameters of blinking
in a way that is correlated with the improvement in motricity,” said
professor Tison. “Using the EyeBrain Tracker enables us to measure
the motricity effect through eye movements, since the blinking
parameters are also linked to the patient’s general motricity. The
patient’s response to this trial is also a predictor of their
reaction to the neurosurgery that will follow.”
The EyeBrain Tracker, which is already used in the early
diagnosis of Parkinsonian syndromes, such as progressive
supra-nuclear paralysis (PSP), cortico-basal degeneration (CBD) and
multiple systems atrophy (MSA), is thus continuing to broaden its
fields of application. It is now playing an important role in
clinical research into other neurological diseases, such as multiple
sclerosis, and is a valuable aid in the early diagnosis and
follow-up of these diseases.
“We are delighted to know that the EyeBrain Tracker is playing a
part in a clinical trial targeting idiopathic Parkinson’s,” said the
chairman of EyeBrain, Serge Kinkingnéhun. “This forms part of our
goal of making the benefits of eye motricity available to a larger
number of people suffering from neurological pathologies.”
Parkinson’s disease is the second most common neurodegenerative
disease after Alzheimer’s. In western countries it affects 0.3% of
the general population. Its prevalence increases with age, reaching
one per cent in the over-60s, and as much as 4% in the over-80s.
There are 100,000 sufferers in France and 8,000 new cases are
diagnosed each year.
Source: Eye Brain